<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font3" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font5" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font6" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font7" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font8" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font9" size="8" family="SymbolMT" color="#000000"/>
<text top="42" left="315" width="62" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="text"><b>Available online</b></text>
<text top="42" left="380" width="176" height="7" font="font2" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="text">http://breast-cancer-research.com/content/8/6/R66</text>
<text top="758" left="511" width="45" height="7" font="font2" id="p1_t3" reading_order_no="166" segment_no="11" tag_type="text">Page 7 of 12</text>
<text top="769" left="436" width="120" height="6" font="font3" id="p1_t4" reading_order_no="167" segment_no="12" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="449" left="57" width="112" height="8" font="font4" id="p1_t5" reading_order_no="100" segment_no="5" tag_type="title"><b>Triple-negative phenotype</b></text>
<text top="461" left="57" width="240" height="9" font="font5" id="p1_t6" reading_order_no="101" segment_no="7" tag_type="text">Of the 136 patients in this study for whom complete biomarker</text>
<text top="473" left="57" width="240" height="9" font="font5" id="p1_t7" reading_order_no="102" segment_no="7" tag_type="text">data were available, 44 had tumors that were found to carry</text>
<text top="485" left="57" width="240" height="9" font="font5" id="p1_t8" reading_order_no="103" segment_no="7" tag_type="text">the triple-negative phenotype (ER negative, PR negative, and</text>
<text top="496" left="57" width="240" height="9" font="font5" id="p1_t9" reading_order_no="104" segment_no="7" tag_type="text">HER2 negative). There was a higher proportion of triple-nega-</text>
<text top="508" left="57" width="240" height="9" font="font5" id="p1_t10" reading_order_no="105" segment_no="7" tag_type="text">tive tumors with over-expression of p53 on IHC, but this result</text>
<text top="520" left="57" width="225" height="9" font="font5" id="p1_t11" reading_order_no="106" segment_no="7" tag_type="text">did not reach statistical significance (53% versus 36%; </text>
<text top="520" left="282" width="9" height="9" font="font6" id="p1_t12" reading_order_no="107" segment_no="7" tag_type="text"><i>P </i></text>
<text top="520" left="291" width="6" height="9" font="font5" id="p1_t13" reading_order_no="108" segment_no="7" tag_type="text">=</text>
<text top="532" left="57" width="240" height="9" font="font5" id="p1_t14" reading_order_no="109" segment_no="7" tag_type="text">0.088). We conducted an exploratory analysis to determine</text>
<text top="543" left="57" width="240" height="9" font="font5" id="p1_t15" reading_order_no="110" segment_no="7" tag_type="text">the objective response rate, TTF, and OS in patients with the</text>
<text top="555" left="57" width="240" height="9" font="font5" id="p1_t16" reading_order_no="111" segment_no="7" tag_type="text">triple-negative phenotype. We found that neither the response</text>
<text top="567" left="57" width="240" height="9" font="font5" id="p1_t17" reading_order_no="112" segment_no="7" tag_type="text">rate nor TTF differed in the triple-negative subgroup as com-</text>
<text top="579" left="57" width="240" height="9" font="font5" id="p1_t18" reading_order_no="113" segment_no="7" tag_type="text">pared with all other patients (response rate: 26% versus 23%,</text>
<text top="590" left="57" width="9" height="9" font="font6" id="p1_t19" reading_order_no="114" segment_no="7" tag_type="text"><i>P </i></text>
<text top="590" left="66" width="183" height="9" font="font5" id="p1_t20" reading_order_no="115" segment_no="7" tag_type="text">= 0.70; TTF: 2.8 months versus 4.5 months, </text>
<text top="590" left="249" width="9" height="9" font="font6" id="p1_t21" reading_order_no="116" segment_no="7" tag_type="text"><i>P </i></text>
<text top="590" left="259" width="38" height="9" font="font5" id="p1_t22" reading_order_no="117" segment_no="7" tag_type="text">= 0.092).</text>
<text top="602" left="57" width="240" height="9" font="font5" id="p1_t23" reading_order_no="118" segment_no="7" tag_type="text">However, the triple-negative phenotype was associated with a</text>
<text top="614" left="57" width="240" height="9" font="font5" id="p1_t24" reading_order_no="119" segment_no="7" tag_type="text">significant decrement in OS (8.6 months versus 12.8 months;</text>
<text top="626" left="57" width="9" height="9" font="font6" id="p1_t25" reading_order_no="120" segment_no="7" tag_type="text"><i>P </i></text>
<text top="626" left="65" width="232" height="9" font="font5" id="p1_t26" reading_order_no="121" segment_no="7" tag_type="text"><a href="">= 0.008; Figure 2)</a>. The results were similar when FISH was</text>
<text top="637" left="57" width="240" height="9" font="font5" id="p1_t27" reading_order_no="122" segment_no="7" tag_type="text">used to determine HER2 negativity in this subgroup (8.8</text>
<text top="649" left="57" width="114" height="9" font="font5" id="p1_t28" reading_order_no="123" segment_no="7" tag_type="text">months versus 11.7 months; </text>
<text top="649" left="171" width="9" height="9" font="font6" id="p1_t29" reading_order_no="124" segment_no="7" tag_type="text"><i>P </i></text>
<text top="649" left="180" width="37" height="9" font="font5" id="p1_t30" reading_order_no="125" segment_no="7" tag_type="text">= 0.038).</text>
<text top="673" left="57" width="190" height="8" font="font4" id="p1_t31" reading_order_no="126" segment_no="9" tag_type="title"><b>Outcomes and biomarkers according to race</b></text>
<text top="684" left="57" width="240" height="9" font="font5" id="p1_t32" reading_order_no="127" segment_no="10" tag_type="text">A total of 105 (22%) of the participants in CALGB 9342 iden-</text>
<text top="696" left="57" width="240" height="9" font="font5" id="p1_t33" reading_order_no="128" segment_no="10" tag_type="text">tified themselves as African-American. An exploratory analysis</text>
<text top="708" left="57" width="240" height="9" font="font5" id="p1_t34" reading_order_no="129" segment_no="10" tag_type="text">showed that the response rate and TTF were similar in African-</text>
<text top="720" left="57" width="240" height="9" font="font5" id="p1_t35" reading_order_no="130" segment_no="10" tag_type="text">American women and Caucasian women. However, the</text>
<text top="449" left="315" width="241" height="9" font="font5" id="p1_t36" reading_order_no="131" segment_no="6" tag_type="text">median OS was significantly shorter among African-American</text>
<text top="461" left="315" width="172" height="9" font="font5" id="p1_t37" reading_order_no="132" segment_no="6" tag_type="text">women (10.1 months versus 13.1 months; </text>
<text top="461" left="487" width="9" height="9" font="font6" id="p1_t38" reading_order_no="133" segment_no="6" tag_type="text"><i>P </i></text>
<text top="461" left="497" width="59" height="9" font="font5" id="p1_t39" reading_order_no="134" segment_no="6" tag_type="text">= 0.0005); the</text>
<text top="473" left="315" width="241" height="9" font="font5" id="p1_t40" reading_order_no="135" segment_no="6" tag_type="text">difference persisted in a multivariate analysis (hazard ratio</text>
<text top="485" left="315" width="110" height="9" font="font5" id="p1_t41" reading_order_no="136" segment_no="6" tag_type="text">1.44, 95% CI 1.13 to 1.84).</text>
<text top="508" left="315" width="240" height="9" font="font5" id="p1_t42" reading_order_no="137" segment_no="8" tag_type="text">The proportion of African-American women in the subset of</text>
<text top="520" left="315" width="151" height="9" font="font5" id="p1_t43" reading_order_no="138" segment_no="8" tag_type="text">patients with biomarker data (20.6%; </text>
<text top="520" left="466" width="8" height="9" font="font6" id="p1_t44" reading_order_no="139" segment_no="8" tag_type="text"><i>n </i></text>
<text top="520" left="475" width="81" height="9" font="font5" id="p1_t45" reading_order_no="140" segment_no="8" tag_type="text">= 34) was similar to</text>
<text top="532" left="315" width="240" height="9" font="font5" id="p1_t46" reading_order_no="141" segment_no="8" tag_type="text">the proportion in the overall group. Tumors were HER2 posi-</text>
<text top="543" left="315" width="240" height="9" font="font5" id="p1_t47" reading_order_no="142" segment_no="8" tag_type="text">tive, according to the CB11 assay, in 9% of African-American</text>
<text top="555" left="315" width="224" height="9" font="font5" id="p1_t48" reading_order_no="143" segment_no="8" tag_type="text">women, as compared with 22% of Caucasian women (</text>
<text top="555" left="540" width="9" height="9" font="font6" id="p1_t49" reading_order_no="144" segment_no="8" tag_type="text"><i>P </i></text>
<text top="555" left="550" width="6" height="9" font="font5" id="p1_t50" reading_order_no="145" segment_no="8" tag_type="text">=</text>
<text top="567" left="315" width="241" height="9" font="font5" id="p1_t51" reading_order_no="146" segment_no="8" tag_type="text">0.08). The percentage of African-American women presenting</text>
<text top="579" left="315" width="240" height="9" font="font5" id="p1_t52" reading_order_no="147" segment_no="8" tag_type="text">with tumors that were negative for ER, PR, and HER2 expres-</text>
<text top="590" left="315" width="240" height="9" font="font5" id="p1_t53" reading_order_no="148" segment_no="8" tag_type="text">sion was more than twice that of Caucasian women (47%</text>
<text top="602" left="315" width="52" height="9" font="font5" id="p1_t54" reading_order_no="149" segment_no="8" tag_type="text">versus 21%; </text>
<text top="602" left="367" width="9" height="9" font="font6" id="p1_t55" reading_order_no="150" segment_no="8" tag_type="text"><i>P </i></text>
<text top="602" left="375" width="180" height="9" font="font5" id="p1_t56" reading_order_no="151" segment_no="8" tag_type="text">=<a href=""> 0.003; Table 7). Both TTF and OS were s</a>ig-</text>
<text top="614" left="315" width="240" height="9" font="font5" id="p1_t57" reading_order_no="152" segment_no="8" tag_type="text">nificantly worse among African-American women than among</text>
<text top="626" left="315" width="78" height="9" font="font5" id="p1_t58" reading_order_no="153" segment_no="8" tag_type="text">Caucasian women (</text>
<text top="626" left="393" width="9" height="9" font="font6" id="p1_t59" reading_order_no="154" segment_no="8" tag_type="text"><i>P </i></text>
<text top="626" left="401" width="51" height="9" font="font5" id="p1_t60" reading_order_no="155" segment_no="8" tag_type="text">= 0.038 and </text>
<text top="626" left="453" width="9" height="9" font="font6" id="p1_t61" reading_order_no="156" segment_no="8" tag_type="text"><i>P </i></text>
<text top="626" left="461" width="95" height="9" font="font5" id="p1_t62" reading_order_no="157" segment_no="8" tag_type="text">= 0.045, respectively), a</text>
<text top="637" left="315" width="241" height="9" font="font5" id="p1_t63" reading_order_no="158" segment_no="8" tag_type="text">difference that persisted in a multivariate analysis (hazard ratio</text>
<text top="649" left="315" width="240" height="9" font="font5" id="p1_t64" reading_order_no="159" segment_no="8" tag_type="text">1.44, 95% CI 1.13 to 1.84). However, when evaluating dis-</text>
<text top="661" left="315" width="240" height="9" font="font5" id="p1_t65" reading_order_no="160" segment_no="8" tag_type="text">ease-free survival and OS in triple-negative tumors, survival did</text>
<text top="673" left="315" width="241" height="9" font="font5" id="p1_t66" reading_order_no="161" segment_no="8" tag_type="text">not differ by race, suggesting that the negative outcome of</text>
<text top="684" left="315" width="241" height="9" font="font5" id="p1_t67" reading_order_no="162" segment_no="8" tag_type="text">African-American women in this cohort is attributable to the</text>
<text top="696" left="315" width="241" height="9" font="font5" id="p1_t68" reading_order_no="163" segment_no="8" tag_type="text">greater proportion of triple-negative tumors and not other</text>
<text top="708" left="315" width="241" height="9" font="font5" id="p1_t69" reading_order_no="164" segment_no="8" tag_type="text">race-related variables (Figure <a href="">2). O</a>f note, there were no signif-</text>
<text top="720" left="315" width="240" height="9" font="font5" id="p1_t70" reading_order_no="165" segment_no="8" tag_type="text">icant differences between the proportions of African-American</text>
<text top="85" left="57" width="28" height="7" font="font0" id="p1_t71" reading_order_no="2" segment_no="1" tag_type="title"><b>Table 5</b></text>
<text top="104" left="57" width="360" height="7" font="font0" id="p1_t72" reading_order_no="3" segment_no="2" tag_type="text"><b>Cox proportional hazards univariate modeling for time to treatment failure and overall survival</b></text>
<text top="123" left="61" width="27" height="7" font="font2" id="p1_t73" reading_order_no="4" segment_no="3" tag_type="table">Variable</text>
<text top="123" left="302" width="82" height="7" font="font2" id="p1_t74" reading_order_no="5" segment_no="3" tag_type="table">Time to treatment failure</text>
<text top="123" left="460" width="51" height="7" font="font2" id="p1_t75" reading_order_no="6" segment_no="3" tag_type="table">Overall survival</text>
<text top="140" left="276" width="75" height="7" font="font2" id="p1_t76" reading_order_no="7" segment_no="3" tag_type="table">Hazard ratio (95% CI)</text>
<text top="140" left="375" width="7" height="7" font="font7" id="p1_t77" reading_order_no="8" segment_no="3" tag_type="table"><i>P </i></text>
<text top="140" left="383" width="17" height="7" font="font2" id="p1_t78" reading_order_no="9" segment_no="3" tag_type="table">value</text>
<text top="140" left="400" width="3" height="5" font="font8" id="p1_t79" reading_order_no="10" segment_no="3" tag_type="table">a</text>
<text top="140" left="418" width="75" height="7" font="font2" id="p1_t80" reading_order_no="11" segment_no="3" tag_type="table">Hazard ratio (95% CI)</text>
<text top="140" left="517" width="7" height="7" font="font7" id="p1_t81" reading_order_no="12" segment_no="3" tag_type="table"><i>P </i></text>
<text top="140" left="525" width="17" height="7" font="font2" id="p1_t82" reading_order_no="13" segment_no="3" tag_type="table">value</text>
<text top="140" left="542" width="3" height="5" font="font8" id="p1_t83" reading_order_no="14" segment_no="3" tag_type="table">a</text>
<text top="159" left="61" width="67" height="7" font="font2" id="p1_t84" reading_order_no="15" segment_no="3" tag_type="table">Univariate modeling</text>
<text top="174" left="71" width="51" height="7" font="font2" id="p1_t85" reading_order_no="16" segment_no="3" tag_type="table">Age &gt;50 years</text>
<text top="174" left="277" width="59" height="7" font="font2" id="p1_t86" reading_order_no="17" segment_no="3" tag_type="table">0.59 (0.42–0.83)</text>
<text top="174" left="375" width="25" height="7" font="font2" id="p1_t87" reading_order_no="18" segment_no="3" tag_type="table">0.0051</text>
<text top="174" left="418" width="59" height="7" font="font2" id="p1_t88" reading_order_no="19" segment_no="3" tag_type="table">0.64 (0.46–0.89)</text>
<text top="174" left="517" width="20" height="7" font="font2" id="p1_t89" reading_order_no="20" segment_no="3" tag_type="table">0.041</text>
<text top="190" left="71" width="122" height="7" font="font2" id="p1_t90" reading_order_no="21" segment_no="3" tag_type="table">Performance status: 0 versus 1 or 2</text>
<text top="190" left="277" width="59" height="7" font="font2" id="p1_t91" reading_order_no="22" segment_no="3" tag_type="table">1.30 (0.95–1.78)</text>
<text top="190" left="375" width="16" height="7" font="font2" id="p1_t92" reading_order_no="23" segment_no="3" tag_type="table">0.11</text>
<text top="190" left="418" width="59" height="7" font="font2" id="p1_t93" reading_order_no="24" segment_no="3" tag_type="table">1.41 (1.03–1.94)</text>
<text top="190" left="517" width="20" height="7" font="font2" id="p1_t94" reading_order_no="25" segment_no="3" tag_type="table">0.031</text>
<text top="205" left="71" width="38" height="7" font="font2" id="p1_t95" reading_order_no="26" segment_no="3" tag_type="table">ER positive</text>
<text top="205" left="277" width="59" height="7" font="font2" id="p1_t96" reading_order_no="27" segment_no="3" tag_type="table">0.78 (0.56–1.08)</text>
<text top="205" left="375" width="16" height="7" font="font2" id="p1_t97" reading_order_no="28" segment_no="3" tag_type="table">0.13</text>
<text top="205" left="418" width="59" height="7" font="font2" id="p1_t98" reading_order_no="29" segment_no="3" tag_type="table">0.61 (0.43–0.84)</text>
<text top="205" left="517" width="25" height="7" font="font2" id="p1_t99" reading_order_no="30" segment_no="3" tag_type="table">0.0029</text>
<text top="221" left="71" width="39" height="7" font="font2" id="p1_t100" reading_order_no="31" segment_no="3" tag_type="table">PR positive</text>
<text top="221" left="277" width="59" height="7" font="font2" id="p1_t101" reading_order_no="32" segment_no="3" tag_type="table">0.72 (0.51–1.00)</text>
<text top="221" left="375" width="16" height="7" font="font2" id="p1_t102" reading_order_no="33" segment_no="3" tag_type="table">0.53</text>
<text top="221" left="418" width="59" height="7" font="font2" id="p1_t103" reading_order_no="34" segment_no="3" tag_type="table">0.71 (0.51–1.00)</text>
<text top="221" left="517" width="20" height="7" font="font2" id="p1_t104" reading_order_no="35" segment_no="3" tag_type="table">0.049</text>
<text top="236" left="71" width="51" height="7" font="font2" id="p1_t105" reading_order_no="36" segment_no="3" tag_type="table">ER/PR positive</text>
<text top="236" left="277" width="59" height="7" font="font2" id="p1_t106" reading_order_no="37" segment_no="3" tag_type="table">0.72 (0.51–1.00)</text>
<text top="236" left="375" width="16" height="7" font="font2" id="p1_t107" reading_order_no="38" segment_no="3" tag_type="table">0.53</text>
<text top="236" left="418" width="59" height="7" font="font2" id="p1_t108" reading_order_no="39" segment_no="3" tag_type="table">0.62 (0.44–0.86)</text>
<text top="236" left="517" width="25" height="7" font="font2" id="p1_t109" reading_order_no="40" segment_no="3" tag_type="table">0.0048</text>
<text top="252" left="71" width="152" height="7" font="font2" id="p1_t110" reading_order_no="41" segment_no="3" tag_type="table">Number of metastatic sites: 0 to 2 versus 3+</text>
<text top="252" left="277" width="59" height="7" font="font2" id="p1_t111" reading_order_no="42" segment_no="3" tag_type="table">1.72 (1.03–2.88)</text>
<text top="252" left="375" width="16" height="7" font="font2" id="p1_t112" reading_order_no="43" segment_no="3" tag_type="table">0.37</text>
<text top="252" left="418" width="59" height="7" font="font2" id="p1_t113" reading_order_no="44" segment_no="3" tag_type="table">1.10 (0.66–1.82)</text>
<text top="252" left="517" width="16" height="7" font="font2" id="p1_t114" reading_order_no="45" segment_no="3" tag_type="table">0.72</text>
<text top="267" left="71" width="73" height="7" font="font2" id="p1_t115" reading_order_no="46" segment_no="3" tag_type="table">Disease-free interval: </text>
<text top="265" left="144" width="4" height="10" font="font9" id="p1_t116" reading_order_no="47" segment_no="3" tag_type="table">≤</text>
<text top="267" left="148" width="81" height="7" font="font2" id="p1_t117" reading_order_no="48" segment_no="3" tag_type="table">2 years versus &gt;2 years</text>
<text top="267" left="276" width="59" height="7" font="font2" id="p1_t118" reading_order_no="49" segment_no="3" tag_type="table">0.72 (0.52–1.00)</text>
<text top="267" left="375" width="16" height="7" font="font2" id="p1_t119" reading_order_no="50" segment_no="3" tag_type="table">0.49</text>
<text top="267" left="418" width="59" height="7" font="font2" id="p1_t120" reading_order_no="51" segment_no="3" tag_type="table">0.81 (0.59–1.12)</text>
<text top="267" left="517" width="16" height="7" font="font2" id="p1_t121" reading_order_no="52" segment_no="3" tag_type="table">0.20</text>
<text top="283" left="71" width="97" height="7" font="font2" id="p1_t122" reading_order_no="53" segment_no="3" tag_type="table">Prior adjuvant chemotherapy</text>
<text top="283" left="277" width="59" height="7" font="font2" id="p1_t123" reading_order_no="54" segment_no="3" tag_type="table">0.87 (0.63–1.20)</text>
<text top="283" left="375" width="16" height="7" font="font2" id="p1_t124" reading_order_no="55" segment_no="3" tag_type="table">0.39</text>
<text top="283" left="418" width="59" height="7" font="font2" id="p1_t125" reading_order_no="56" segment_no="3" tag_type="table">0.93 (0.68–1.29)</text>
<text top="283" left="517" width="16" height="7" font="font2" id="p1_t126" reading_order_no="57" segment_no="3" tag_type="table">0.67</text>
<text top="298" left="71" width="82" height="7" font="font2" id="p1_t127" reading_order_no="58" segment_no="3" tag_type="table">HER2 positive by CB11</text>
<text top="298" left="277" width="59" height="7" font="font2" id="p1_t128" reading_order_no="59" segment_no="3" tag_type="table">1.44 (0.97–2.15)</text>
<text top="298" left="375" width="16" height="7" font="font2" id="p1_t129" reading_order_no="60" segment_no="3" tag_type="table">0.68</text>
<text top="298" left="418" width="59" height="7" font="font2" id="p1_t130" reading_order_no="61" segment_no="3" tag_type="table">1.34 (0.91–1.99)</text>
<text top="298" left="517" width="16" height="7" font="font2" id="p1_t131" reading_order_no="62" segment_no="3" tag_type="table">0.41</text>
<text top="314" left="71" width="78" height="7" font="font2" id="p1_t132" reading_order_no="63" segment_no="3" tag_type="table">HER2 positive by FISH</text>
<text top="314" left="277" width="59" height="7" font="font2" id="p1_t133" reading_order_no="64" segment_no="3" tag_type="table">1.22 (0.85–1.76)</text>
<text top="314" left="375" width="16" height="7" font="font2" id="p1_t134" reading_order_no="65" segment_no="3" tag_type="table">0.29</text>
<text top="314" left="418" width="59" height="7" font="font2" id="p1_t135" reading_order_no="66" segment_no="3" tag_type="table">1.24 (0.86–1.79)</text>
<text top="314" left="517" width="16" height="7" font="font2" id="p1_t136" reading_order_no="67" segment_no="3" tag_type="table">0.25</text>
<text top="329" left="71" width="132" height="7" font="font2" id="p1_t137" reading_order_no="68" segment_no="3" tag_type="table">HER2 by HercepTest: 0–1 versus 2–3</text>
<text top="329" left="277" width="59" height="7" font="font2" id="p1_t138" reading_order_no="69" segment_no="3" tag_type="table">1.02 (0.73–1.43)</text>
<text top="329" left="375" width="16" height="7" font="font2" id="p1_t139" reading_order_no="70" segment_no="3" tag_type="table">0.90</text>
<text top="329" left="418" width="59" height="7" font="font2" id="p1_t140" reading_order_no="71" segment_no="3" tag_type="table">1.04 (0.74–1.46)</text>
<text top="329" left="517" width="16" height="7" font="font2" id="p1_t141" reading_order_no="72" segment_no="3" tag_type="table">0.83</text>
<text top="345" left="71" width="122" height="7" font="font2" id="p1_t142" reading_order_no="73" segment_no="3" tag_type="table">HER2 by HercepTest: 0–2 versus 3</text>
<text top="345" left="277" width="59" height="7" font="font2" id="p1_t143" reading_order_no="74" segment_no="3" tag_type="table">1.34 (0.91–1.98)</text>
<text top="345" left="375" width="16" height="7" font="font2" id="p1_t144" reading_order_no="75" segment_no="3" tag_type="table">0.14</text>
<text top="345" left="418" width="59" height="7" font="font2" id="p1_t145" reading_order_no="76" segment_no="3" tag_type="table">1.11 (0.76–1.64)</text>
<text top="345" left="517" width="16" height="7" font="font2" id="p1_t146" reading_order_no="77" segment_no="3" tag_type="table">0.59</text>
<text top="360" left="61" width="72" height="7" font="font2" id="p1_t147" reading_order_no="78" segment_no="3" tag_type="table">Multivariate modeling</text>
<text top="376" left="71" width="51" height="7" font="font2" id="p1_t148" reading_order_no="79" segment_no="3" tag_type="table">Age &gt;50 years</text>
<text top="376" left="277" width="59" height="7" font="font2" id="p1_t149" reading_order_no="80" segment_no="3" tag_type="table">0.99 (0.97–1.00)</text>
<text top="376" left="375" width="20" height="7" font="font2" id="p1_t150" reading_order_no="81" segment_no="3" tag_type="table">0.045</text>
<text top="376" left="418" width="59" height="7" font="font2" id="p1_t151" reading_order_no="82" segment_no="3" tag_type="table">0.99 (0.97–1.00)</text>
<text top="376" left="517" width="16" height="7" font="font2" id="p1_t152" reading_order_no="83" segment_no="3" tag_type="table">0.10</text>
<text top="391" left="71" width="51" height="7" font="font2" id="p1_t153" reading_order_no="84" segment_no="3" tag_type="table">ER/PR positive</text>
<text top="391" left="277" width="59" height="7" font="font2" id="p1_t154" reading_order_no="85" segment_no="3" tag_type="table">1.28 (0.89–1.82)</text>
<text top="391" left="375" width="16" height="7" font="font2" id="p1_t155" reading_order_no="86" segment_no="3" tag_type="table">0.18</text>
<text top="391" left="418" width="59" height="7" font="font2" id="p1_t156" reading_order_no="87" segment_no="3" tag_type="table">1.55 (1.08–2.22)</text>
<text top="391" left="517" width="20" height="7" font="font2" id="p1_t157" reading_order_no="88" segment_no="3" tag_type="table">0.017</text>
<text top="407" left="71" width="163" height="7" font="font2" id="p1_t158" reading_order_no="89" segment_no="3" tag_type="table">HER2 negative on HercepTest: 0–1 versus 2–3</text>
<text top="407" left="276" width="59" height="7" font="font2" id="p1_t159" reading_order_no="90" segment_no="3" tag_type="table">0.97 (0.68–1.40)</text>
<text top="407" left="375" width="16" height="7" font="font2" id="p1_t160" reading_order_no="91" segment_no="3" tag_type="table">0.88</text>
<text top="407" left="418" width="59" height="7" font="font2" id="p1_t161" reading_order_no="92" segment_no="3" tag_type="table">0.93 (0.65–1.35)</text>
<text top="407" left="517" width="16" height="7" font="font2" id="p1_t162" reading_order_no="93" segment_no="3" tag_type="table">0.71</text>
<text top="423" left="61" width="3" height="5" font="font8" id="p1_t163" reading_order_no="94" segment_no="4" tag_type="text">a</text>
<text top="423" left="64" width="7" height="7" font="font7" id="p1_t164" reading_order_no="95" segment_no="4" tag_type="text"><i>P </i></text>
<text top="423" left="71" width="385" height="7" font="font2" id="p1_t165" reading_order_no="96" segment_no="4" tag_type="text">values were calculated using the log-rank test. CI, confidence interval; ER, estrogen receptor; FISH, fluorescence </text>
<text top="423" left="456" width="23" height="7" font="font7" id="p1_t166" reading_order_no="97" segment_no="4" tag_type="text"><i>in situ </i></text>
<text top="423" left="479" width="61" height="7" font="font2" id="p1_t167" reading_order_no="98" segment_no="4" tag_type="text">hybridization; PR, </text>
<text top="431" left="61" width="78" height="7" font="font2" id="p1_t168" reading_order_no="99" segment_no="4" tag_type="text">progesterone receptor.</text>
</page>
</pdf2xml>
